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while growing up I worked in my father’s fruit and
egetable store, went with him to buy produce at the local
armer’s market, and helped him sell Christmas trees and
owers at Easter. I was thereby afforded a rich experience in
he process of negotiating price and selling goods in the
arketplace. It rapidly became apparent that the price for
any items depended on how they were marketed and what
omeone could be convinced to pay for them. For some
eason, it seemed that this characteristic did not apply to
harmaceuticals. Recently, however, several instances of
arketing and selling of prescription drugs have demon-
trated that the same principles do seem to apply.
The first example of the differential pricing of pharma-
euticals that I became aware of related to the drug
nasteride, which was marketed as Proscar to treat prostatic
ypertrophy. After its introduction, it became clear that the
gent was also capable of inducing hair growth, and it was
pproved as Propecia to treat baldness. However, the price
or the agent varied considerably for the two indications.
ur local pharmacies currently chart $2.00 out of pocket for
1-mg pill of Propecia but $3.00 for a 5-mg Proscar pill.
bviously, breaking the 5-mg Proscar in even quarters
ould reduce the cost to $0.75. Because Propecia could be
onsidered a discretionary “quality-of-life” drug, the price
ifferential did not make much of an impression.
A similar example of variable pricing has recently oc-
urred with sildenafil. When sold for erectile dysfunction as
iagra, a 50-mg pill costs about $1.15; when sold as Revatio
o treat pulmonary hypertension, a 20-mg pill costs about
he same. Splitting a 50-mg Viagra in two would half the
rice of the agent for a patient for whom Revatio is
rescribed. This could be especially significant because
evatio is to be taken three times per day. Of course, the
umber of patients with pulmonary hypertension is presum-
bly much less than those with erectile dysfunction.
The foregoing situations were brought into focus by the
ecent approval of BiDil. This drug is the first to be
pproved for a specific race, and it raises a number of
edical as well as financial issues. As is well known, BiDil
s a combination of hydralazine and isosorbide dinitrate
pproved for the treatment of heart failure in self-identified
lacks. Although evidence exists that the mechanism of
enefit of the agent may be related to the reduced produc-
ion of nitric oxide in blacks, this is not established with
ertainty. Environmental influence cannot be completely
uled out. Similarly, it is unclear whether a genetic basis axists for the superior response to this drug combination by
lacks than by whites. If a genetic basis does exist, can skin
olor serve as an adequate marker? The degree of racial
ntermixing that has occurred over the years calls into
uestion the genetic significance of skin color. In fact, it is
ecoming increasingly difficult to judge the significance of
anuscripts studying blacks or African Americans due to
he increasing prevalence of multiracial individuals.
But I digress; it was the financial implications of BiDil
hat were being discussed. Hydralazine and isosorbide, of
ourse, are old drugs that have long since gone off patent.
hecking again with a local pharmacy, a 20-mg isosorbide
ill costs $0.50 and either 25- or 50-mg tablets of hydral-
zine sell for approximately $0.80. In contrast, BiDil, which
ontains 37.5 mg hydralazine and 20 mg isosorbide, sells for
bout $2.36. Thus, BiDil is nearly twice as expensive as its
ndividual components. Although the prices at the Univer-
ity of California at San Diego (UCSD) pharmacy are
omewhat lower, the differences are comparable.
Drug combinations with variable pricing have also figured
rominently in the marketing of statins. Atorvastatin and
he calcium-channel blocker amlodipine have been com-
ined into Caduet, which actually varies from $0.44 more to
0.20 less per pill as a 5/20 combination than the equivalent
oses of individual pills. Vitorin, the marriage of the
ipid-lowering agents simvastatin and ezetimibe, is actually
uch less expensive at $2.50 for a 10/20 pill than the $6.30
harged for the same doses separately. Competitive pricing
ay play a role in this, because an equivalent dose of
torvastatin and ezetimibe would be $5.40.
We are perhaps witnessing the epitome of combination
rug marketing with the advent of the clinical trials of
orcetrapib. This agent is a cholesterol ester transfer protein
nhibitor that has been shown to have the potential to
roduce a 50% to 100% increase in high-density lipoprotein,
therapeutic target that has so far eluded us. However, the
ivotal clinical trials, for which I am an investigator, are all
xamining the efficacy of the combination of torcetrapib and
torvastatin, and not the agent alone as an add-on to
ow-density lipoprotein-lowering therapy. Thus, evidence-
ased medicine will only have data for torcetrapib/
torvastatin to guide usage, and approval by the Food and
rug Administration will likely be limited to the combina-
ion preparation. The drug will likely be unavailable to those
ho cannot tolerate statins and will help sustain the price oftorvastatin even after it goes off patent. Many prior drug
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ad advantages both in the scientific field and in the
arketplace. Torcetrapib, however, represents the initial
xample of an agent whose research program is based on
ombined therapy, a factor that will have major implications
n the pricing and selling of this drug as well as that of
torvastatin.
Let me issue a disclaimer and concede that I do not have
n MBA nor am I experienced in the world of business. I
m not very knowledgeable about issues such as unit cost
nd pricing or the expenses entailed in drug development,
arketing, and advertising. Therefore, it is perhaps not
urprising that I do not understand the various pricing
chemes just presented. However, I find it inescapable that
uch of the approach to selling prescription drugs is similar
o that applied to selling used cars, life insurance, Christmas
rees, or most other commodities. It is clear that the
harmaceutical industry must be profitable to perform
esearch and develop new drugs and that society has aenefited enormously from its accomplishments. No one
ould want to hinder the innovative work of pharmaceutical
ompanies in any way. However, the treatment of disease is
ot discretionary on the part of the patient, and the calling
o cure disease and ease suffering has been afforded a high
tation by society. It would be a shame if that patina of
obility was tarnished by machinations in the marketplace,
specially if such actions placed important medications
eyond the financial reach of those who need them. I urge
he pharmaceutical industry, and those agencies responsible
o oversee it, to work to make the prices for prescription
rugs as rational and cost effective as possible, and to ensure
hat new agents are evaluated to be applicable in the
roadest possible clinical settings.
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